Financial Performance - The company's operating revenue for 2021 was CNY 309,072,018.55, representing a 20.75% increase compared to CNY 255,963,220.94 in 2020[17]. - The net profit attributable to shareholders for 2021 was CNY 87,119,688.54, a 41.57% increase from CNY 61,538,234.33 in 2020[17]. - The net profit after deducting non-recurring gains and losses was CNY 80,371,540.97, up 34.76% from CNY 59,640,775.03 in 2020[17]. - The net cash flow from operating activities was CNY 175,550,139.58, an increase of 24.93% compared to CNY 140,517,444.56 in 2020[17]. - The total assets at the end of 2021 reached CNY 1,001,235,522.57, a 37.14% increase from CNY 730,072,786.50 at the end of 2020[17]. - The net assets attributable to shareholders at the end of 2021 were CNY 845,553,406.64, reflecting a 40.65% increase from CNY 601,175,030.08 at the end of 2020[17]. - The basic earnings per share for 2021 were CNY 0.3520, a 13.26% increase from CNY 0.3108 in 2020[17]. - The weighted average return on equity for 2021 was 11.27%, up from 9.78% in 2020[17]. Revenue Sources and Growth - The company's total revenue for the four quarters was approximately 309.07 million, with the highest revenue in Q3 at 82.49 million, representing a 20% increase from Q1[19]. - The revenue from irradiation technology services accounted for 92.22% of total revenue, amounting to ¥285,019,312.30, with a year-on-year growth of 22.25%[73]. - The main source of revenue is from irradiation technology services, with an upward trend in profitability due to increasing demand and market expansion[40]. - The company is focused on expanding its irradiation sterilization services for medical products, food, and packaging materials, which are its main revenue sources[29]. Research and Development - Research and development expenses amounted to CNY 21,089,583.24, an increase of 18.23% year-on-year, indicating a rise in R&D investment[68]. - The company launched 34 new technology research projects in 2021, including automatic systems for gamma irradiation facilities, and obtained 2 invention patents and 26 utility model patents[54]. - The company added 26 new technology research and development patents and 7 software copyrights in 2021, bringing the total to 179 patents and 65 copyrights[71]. - The number of R&D personnel increased by 19.13% from 115 in 2020 to 137 in 2021, with R&D personnel now accounting for 24.29% of the total workforce[88]. Operational Efficiency - The operational efficiency improved with a 9.3 million CNY increase in labor productivity per person compared to the previous year[70]. - The company has implemented an information management system to improve operational efficiency and service traceability[45]. - The company has established a quality management system compliant with international standards, ensuring service quality and customer satisfaction[44]. - The company has maintained stable operational performance despite local pandemic outbreaks, providing uninterrupted irradiation sterilization services for medical products[51]. Market Expansion and Strategy - The company is actively seeking new growth opportunities through both organic growth and external expansion, aiming to increase its market presence and investment layout[115]. - The company has expanded its irradiation service network across key economic regions, enhancing its market presence and reducing single-market risks[60]. - The company is developing a project in Zhejiang for sterilizing 300,000 cubic meters of medical devices annually, indicating market expansion efforts[43]. - The company achieved a significant revenue increase in the Central China region, with a growth rate of 58.70%[74]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations[128]. - The company maintains independent operations in terms of assets, personnel, finance, organization, and business, with no asset occupation by the controlling shareholder[132][133]. - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating a clean compliance record[160]. - The company has a comprehensive strategy for talent management, focusing on performance evaluation and compensation linked to company performance[161]. Shareholder Engagement - The company held two shareholder meetings during the reporting period, both conducted with a combination of on-site and online voting, ensuring all resolutions were passed legally and effectively[124]. - A total of 13 questions were raised by investors during the online earnings briefing, focusing on operational performance, pandemic impacts, quality advantages, and business development[120]. - The annual shareholders meeting had a participation rate of 69.58% on May 18, 2021[138]. - The first extraordinary shareholders meeting had a participation rate of 60.00% on December 29, 2021[138]. Corporate Social Responsibility - The company actively fulfills its corporate social responsibility by promoting safety, health, and environmental protection[188]. - The company provided sterilization services for epidemic prevention products, generating approximately 900 million yuan in revenue for the year 2021[192]. - The company received recognition from the National Atomic Energy Agency and industry associations for its outstanding contributions during the pandemic[192]. - The company actively participated in social responsibility initiatives, including poverty alleviation and support for children in need[193]. Future Outlook - The company aims to achieve an annual revenue target of 322.02 million and a net profit target of 90.10 million for 2022, indicating a growth strategy focused on expanding market share[115]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues to reach approximately 1.65 billion RMB[150]. - The company is positioned to benefit from favorable industry policies and a growing market demand for non-power nuclear technology applications, which are recognized as strategic emerging industries[112][114].

Financial Performance - The company's operating revenue for Q1 2022 was ¥78,834,006.63, representing a 15.00% increase compared to ¥68,551,289.98 in the same period last year[4] - The net profit attributable to shareholders for Q1 2022 was ¥28,482,576.99, a 24.43% increase from ¥22,890,054.71 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥28,140,472.98, up 27.40% from ¥22,087,724.13 in the previous year[4] - The net cash flow from operating activities for Q1 2022 was ¥38,146,128.83, reflecting a 27.18% increase compared to ¥29,993,137.21 in the same period last year[4] - Total operating revenue for Q1 2022 was CNY 78,834,006.63, an increase from CNY 68,551,289.98 in the previous period[16] - Net profit for Q1 2022 reached CNY 29,469,515.58, up from CNY 23,295,330.69 in the same period last year, representing a growth of approximately 26.5%[17] - The total comprehensive income for Q1 2022 was ¥29,469,515.58, up from ¥23,295,330.69 in Q1 2021, reflecting an increase of 26.5%[18] Cash Flow and Investments - The net cash flow from operating activities for Q1 2022 was ¥38,146,128.83, an increase of 27.1% compared to ¥29,993,137.21 in Q1 2021[20] - Total cash inflow from operating activities was ¥73,072,873.94, compared to ¥65,825,411.63 in the previous year, indicating a growth of 10.2%[20] - The total cash outflow from operating activities was ¥34,926,745.11, slightly down from ¥35,832,274.42 in Q1 2021, showing a decrease of 2.5%[20] - The cash and cash equivalents at the end of Q1 2022 amounted to ¥336,538,005.28, an increase from ¥260,117,956.74 at the end of Q1 2021, representing a growth of 29.3%[22] - The company reported a net cash outflow from investing activities of ¥16,782,677.28, compared to a net outflow of ¥16,556,230.77 in the same period last year[22] - The net cash flow from financing activities was negative at ¥290,314.80, a significant decrease from a positive cash flow of ¥208,544,360.38 in Q1 2021[22] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,033,994,702.85, a 3.27% increase from ¥1,001,235,522.57 at the end of the previous year[4] - Total liabilities stood at CNY 127,520,930.97, slightly up from CNY 124,231,266.27 at the start of the year[14] - The company's total equity increased to CNY 906,473,771.88 from CNY 877,004,256.30 at the beginning of the year, reflecting a growth of approximately 3.4%[14] - Cash and cash equivalents increased to CNY 336,538,005.28 from CNY 315,464,868.53 at the beginning of the year, reflecting a growth of approximately 6.8%[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,451[8] - The basic and diluted earnings per share for Q1 2022 were both ¥0.1079, up from ¥0.0882 in Q1 2021, reflecting a growth of 22.4%[18] Research and Development - Research and development expenses increased by 37.91% year-on-year, indicating a focus on expanding the application of irradiation technology[7] - Research and development expenses for Q1 2022 were CNY 4,477,839.20, compared to CNY 3,246,845.81 in the previous year, marking an increase of about 38.0%[17] Accounts Receivable and Prepayments - Accounts receivable grew by 90.33% compared to the end of the previous year, attributed to increased market development efforts and significant revenue growth[7] - Prepayments increased by 1012.99% compared to the end of the previous year, primarily due to increased advance payments to suppliers[7] - Accounts receivable rose to CNY 30,407,601.17, up from CNY 15,975,952.18, indicating a significant increase of about 90.5%[12] Inventory - Inventory decreased to CNY 341,900.43 from CNY 701,855.18, showing a reduction of approximately 51.3%[12] Tax Refunds - The company received tax refunds amounting to ¥1,000,304.11 during Q1 2022, compared to ¥1,233.98 in the previous year, indicating a substantial increase[20]

Financial Performance - Revenue for Q3 2021 reached ¥82,494,721.29, an increase of 18.58% year-over-year, and total revenue for the year-to-date was ¥229,842,284.49, up 26.29% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2021 was ¥28,568,532.22, representing a growth of 30.36% year-over-year, while year-to-date net profit reached ¥81,372,705.04, up 75.09% compared to the same period last year[2]. - Operating revenue for the current period was CNY 229,842,284.49, compared to CNY 181,993,794.80 in the previous period, reflecting an increase of approximately 26.3%[15]. - The net profit for Q3 2021 was 85,211,162.32, a significant increase from 46,518,506.98 in Q3 2020, representing an increase of approximately 83.1%[16]. - Basic and diluted earnings per share for Q3 2021 were both 0.3362, compared to 0.2347 in Q3 2020, reflecting a growth of about 43.4%[17]. - Operating profit for Q3 2021 reached 98,499,484.91, up from 55,840,776.44 in the same period last year, indicating an increase of approximately 76.3%[16]. - Total comprehensive income for Q3 2021 was 85,211,162.32, compared to 46,518,506.98 in Q3 2020, showing an increase of approximately 83.1%[16]. - The total revenue from sales of goods and services received in Q3 2021 was 233,760,003.23, compared to 196,116,048.16 in Q3 2020, reflecting an increase of approximately 19.2%[18]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥999,228,971.38, a 36.87% increase from the end of the previous year[2]. - As of September 30, 2021, total assets amounted to CNY 999,228,971.38, an increase from CNY 730,072,786.50 at the end of 2020, representing a growth of approximately 36.8%[12]. - Total current assets reached CNY 357,135,462.97, significantly up from CNY 77,414,229.84, indicating a growth of about 360.5%[13]. - The total liabilities amounted to CNY 127,820,754.81, compared to CNY 100,591,420.27 in the previous period, indicating an increase of approximately 26.9%[14]. - The company's equity attributable to shareholders reached CNY 839,806,423.14, up from CNY 601,175,030.08, representing a growth of about 39.6%[14]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥165,362,246.87, reflecting a 62.31% increase compared to the previous year[2]. - Cash flow from operating activities for Q3 2021 was 165,362,246.87, compared to 101,883,206.69 in Q3 2020, marking an increase of about 62.3%[18]. - The company reported cash and cash equivalents of CNY 297,006,540.87 as of September 30, 2021, a significant increase from CNY 38,136,107.20 at the end of 2020[12]. - Cash and cash equivalents at the end of Q3 2021 amounted to 297,006,540.87, up from 75,690,961.49 at the end of Q3 2020, representing an increase of about 292.5%[19]. - The company reported a net cash outflow from investing activities of -38,914,024.11 for Q3 2021, an improvement from -56,755,699.76 in Q3 2020[19]. - Cash flow from financing activities for Q3 2021 was 132,421,628.25, compared to -31,433,490.81 in Q3 2020, indicating a turnaround in financing activities[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,598, with the largest shareholder, China National Gold Group Corporation, holding 54.20% of the shares[8]. Expenses and Investments - The company experienced a 34.27% decrease in sales expenses year-to-date, mainly due to the reclassification of transportation costs to operating costs under new revenue recognition standards[6]. - Research and development expenses for the current period were CNY 12,471,888.52, compared to CNY 10,990,355.55 in the previous period, reflecting an increase of approximately 13.5%[15]. - The company plans to invest CNY 45 million in the expansion of the electronic accelerator project in Chengdu, covering an area of approximately 9 acres[10]. - The company aims to enhance regional market competitiveness through the new electronic accelerator project, which will complement existing facilities[10]. Other Income and Receivables - The company reported a 124.55% increase in other income year-to-date, primarily due to increased government subsidies and compensation received[6]. - Accounts receivable increased by 101.40% compared to the end of the previous year, attributed to increased market development efforts and new customer acquisition[6]. Earnings Per Share - The company's basic earnings per share for Q3 2021 was ¥0.1082, a decrease of 2.26% year-over-year, while diluted earnings per share remained the same[2].

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 147,347,563.20, representing a 31.06% increase compared to RMB 112,426,661.13 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached RMB 52,804,172.82, a significant increase of 115.00% from RMB 24,560,549.97 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was RMB 47,905,659.83, up 103.72% from RMB 23,515,359.25 year-on-year[20]. - The net cash flow from operating activities was RMB 118,958,590.21, reflecting a 105.37% increase compared to RMB 57,924,775.70 in the same period last year[20]. - Basic earnings per share increased by 84.35% to RMB 0.2286 from RMB 0.1240 in the previous year[20]. - The gross profit margin for irradiation technology services was 64.33%, up by 7.07% compared to the previous year, indicating improved efficiency[69]. - The company reported a significant increase in cash and cash equivalents, which rose by 692.37% to RMB 235,006,637.67, primarily due to funds raised from its public offering[67]. - The company's total equity rose to CNY 841,977,917.25 from CNY 629,481,366.23, reflecting an increase of approximately 33.7%[156]. - The company reported a comprehensive income total of CNY 21,896,607.26, compared to CNY 9,216,576.55 in the previous year[169]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 970,279,685.79, a 32.90% increase from RMB 730,072,786.50 at the end of the previous year[20]. - The total amount of funds raised is RMB 19,949.90 million, with RMB 3,616.39 million utilized during the reporting period and a cumulative investment of RMB 7,872.77 million as of the end of the reporting period[78]. - Total current liabilities decreased to CNY 33,072,136.74 from CNY 53,656,863.05, a reduction of about 38.5%[155]. - The company's accounts receivable increased to CNY 27,344,508.09 from CNY 15,618,327.32, which is an increase of approximately 74.9%[153]. - The company's long-term payables increased significantly to CNY 38,399,478.17 from CNY 1,526,279.61, representing a growth of approximately 2515.5%[155]. Market and Operations - The company primarily provides irradiation sterilization services for medical products, food, pharmaceuticals, and packaging materials, which are its main sources of revenue and profit[30]. - The company operates in seven regional centers across major cities, providing stable and reliable irradiation services[41]. - The company has seen significant growth in the domestic irradiation technology service industry, with increasing market demand and improved technology levels[29]. - The company is a leading enterprise in the irradiation technology service industry in China, with a national layout of 10 gamma irradiation facilities and 1 electron accelerator facility[53]. - The company has established long-term stable partnerships with over 30 Fortune 500 companies, including Johnson & Johnson and Asahi Kasei, contributing to a strong customer base[62]. Research and Development - The company has invested in 34 new technology research projects in the first half of 2021, including the development of an automatic switching system for gamma irradiation facilities[57]. - Research and development expenses increased slightly by 2.02% to ¥7,529,989.48, reflecting ongoing investment in innovation[67]. - The company has allocated CNY 300,000 million for new technology research and development initiatives[185]. Risk Management - The company emphasizes the importance of risk awareness and has outlined its risk management strategies in the report[5]. - The company is facing risks related to potential COVID-19 outbreaks, market demand fluctuations, and safety and environmental concerns, and is taking measures to mitigate these risks[89]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[95]. - The largest shareholder, China Gold Group, holds 54.20% of the shares, totaling 143,099,938 shares[138]. - The total number of ordinary shareholders at the end of the reporting period was 34,710[137]. - The net amount raised from the IPO was RMB 199.50 million, which will be used for future business expansion and development[135]. Compliance and Governance - The semi-annual financial report has not been audited[109]. - The company has ensured effective communication with investors through multiple platforms, respecting the rights of minority shareholders[99]. - There were no significant environmental penalties or violations reported during the period[98].

Financial Performance - The company's revenue for Q1 2021 was ¥68,551,289.98, representing a 62.61% increase compared to ¥42,157,957.36 in the same period last year[8]. - Net profit attributable to shareholders reached ¥22,890,054.71, a significant increase of 778.18% from ¥2,606,541.85 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥22,087,724.13, up 1,030.70% from ¥1,953,454.09 in the previous year[8]. - Basic earnings per share rose to ¥0.0882, reflecting a 521.13% increase from ¥0.0142 in the previous year[8]. - Operating profit surged to ¥27,179,641.55, compared to ¥3,194,503.68 in the prior period, indicating a substantial increase of approximately 751.5%[42]. - Net profit for the current period was ¥23,295,330.69, up from ¥2,805,353.41, reflecting an increase of around 728.5%[42]. Cash Flow - The net cash flow from operating activities was ¥29,993,137.21, an increase of 221.88% compared to ¥9,318,196.24 in the same period last year[8]. - Cash flow from operating activities amounted to ¥64,485,326.05, compared to ¥38,925,031.49 in the previous period, indicating an increase of about 65.7%[48]. - Operating cash inflow for the first quarter was CNY 65,825,411.63, an increase from CNY 43,117,982.61 in the previous period, representing a growth of approximately 52.5%[49]. - Net cash flow from operating activities was CNY 29,993,137.21, significantly higher than CNY 9,318,196.24 in the same period last year, indicating a year-over-year increase of about 221.5%[49]. - The company reported a net cash inflow of CNY 221,981,848.95 for the quarter, compared to a net outflow of CNY 6,255,409.46 in the same quarter last year[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥961,208,203.55, a 31.66% increase from ¥730,072,786.50 at the end of the previous year[8]. - Current assets rose significantly to CNY 306,126,406.50, compared to CNY 77,414,229.84 at the end of 2020, marking an increase of about 295.5%[31]. - The company's total liabilities amounted to CNY 108,932,515.09, up from CNY 100,591,420.27, indicating a rise of about 3.3%[33]. - Shareholders' equity increased to CNY 852,275,688.46 from CNY 629,481,366.23, showing a growth of approximately 35.4%[35]. - The total liabilities to equity ratio improved to approximately 12.8% from 16.0%, indicating a stronger equity position[33]. Market Development - The company added 111 new customers during the reporting period, contributing to an increase in market share[20]. - Revenue for the reporting period increased by 62.61% year-over-year, reaching 68.55 million, attributed to the low revenue base from the previous year due to the pandemic[17]. - Net profit surged by 730.39% year-over-year, amounting to 22.89 million, as a result of enhanced market development and increased customer orders[17]. Future Strategies and Risks - The company aims to achieve a revenue target of 266.59 million and a net profit target of 70.67 million for the year[19]. - Future strategies include strengthening technological innovation and expanding into new markets, particularly in sterilization services and radiation technology applications[21]. - Risks identified include potential pandemic resurgence, market demand fluctuations, and safety/environmental risks associated with nuclear technology applications[24].

Financial Performance - The company's operating revenue for 2020 was approximately ¥255.96 million, representing a 1.07% increase from ¥253.26 million in 2019[17]. - The net profit attributable to shareholders for 2020 was approximately ¥61.54 million, reflecting a 5.54% increase compared to ¥58.31 million in 2019[17]. - The net cash flow from operating activities for 2020 was approximately ¥140.52 million, which is an 11.61% increase from ¥125.90 million in 2019[17]. - The basic earnings per share for 2020 was ¥0.3108, up 5.53% from ¥0.2945 in 2019[17]. - The total assets at the end of 2020 were approximately ¥730.07 million, a decrease of 3.82% from ¥759.03 million at the end of 2019[17]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥601.18 million, a slight increase of 0.41% from ¥598.74 million at the end of 2019[17]. - The company reported a quarterly revenue of approximately ¥73.97 million in Q4 2020, with a net profit of approximately ¥15.06 million for the same quarter[19]. - The company’s weighted average return on equity for 2020 was 9.78%, slightly up from 9.68% in 2019[17]. - The net profit after deducting non-recurring gains and losses for 2020 was approximately ¥59.64 million, which is a 5.98% increase from ¥56.28 million in 2019[17]. - The company reported a non-recurring gain of CNY 1,897,459.30 in 2020, a decrease from CNY 2,032,790.60 in 2019, reflecting a decline of approximately 6.6% year-over-year[23]. Business Operations - The main business of the company is irradiation technology services, which includes sterilization services for medical products, food, pharmaceuticals, and packaging materials, contributing significantly to revenue and profit[26]. - The company utilizes cobalt-60 to provide gamma-ray irradiation services, which effectively sterilizes medical products without the need for repackaging, thus preventing secondary contamination[27]. - The irradiation sterilization service for food helps in extending shelf life while maintaining nutritional value, covering products such as fresh poultry, frozen foods, and pet food[29]. - The company’s revenue primarily comes from irradiation technology services, benefiting from the growing demand driven by national economic growth and continuous market expansion efforts[37]. - The company operates a regional management model with service centers in seven major cities, ensuring stable and reliable irradiation services[36]. - The company’s profitability is characterized by a scale effect, where fixed costs related to cobalt sources do not change with service volume, leading to increased profit margins as revenue scales up[38]. - The company has established a procurement system based on demand, implementing a budget management system for procurement activities[39]. - The company’s irradiation modification services improve the physical and chemical properties of polymer materials, which are widely used in various industries including aerospace and automotive[34]. - The company operates 11 gamma irradiation facilities and 1 electron accelerator across 7 major cities, with a project in Zhejiang for sterilizing 300,000 cubic meters of medical devices under construction[41]. - The company has established a quality management system compliant with international standards, receiving over 30 second-party audits and maintaining certifications from BSI, TUV, and others[42]. Market and Customer Relations - The company has seen a positive impact on business performance due to increased sterilization demand for medical products related to the pandemic, despite some negative effects from operational disruptions[47]. - The company is expanding its market presence by enhancing customer service, increasing irradiation technology applications, and maintaining long-term relationships with core clients[47]. - The company has developed customized sterilization solutions based on client needs, ensuring service quality through full-process monitoring of irradiation doses[43]. - The company has a sales management system that coordinates market development plans across subsidiaries, focusing on long-term partnerships with key clients[44]. - The company has strengthened resource sharing among regional sites to improve cobalt utilization and enhance bargaining power[48]. - The company is committed to maintaining compliance with regulatory requirements for cobalt source procurement and transportation, ensuring safety and operational efficiency[40]. Research and Development - In 2020, the company initiated 29 new technology research projects, filed 1 invention patent, and 34 utility model patents, along with 3 software copyrights[56]. - The company has maintained a stable core technical team, ensuring no significant changes during the reporting period[57]. - The company has established a comprehensive quality management system in accordance with international standards, ensuring reliable dose measurement and product quality[58]. - The company launched 17 new applications in the field of irradiation technology during the reporting period[95]. - The number of R&D personnel was 115, accounting for 20.35% of the total workforce[96]. Financial Management and Dividend Policy - The company plans to distribute a cash dividend of ¥1.6 per 10 shares to all shareholders, based on a total of 264,001,897 shares[5]. - The cash dividend distributed in 2020 accounted for 100% of the total distributable profit of 43,398,186.88 yuan[125]. - The company has consistently maintained a cash dividend distribution policy over the past three years[126]. - The total cash dividend for 2020 was 42,240,303.52 yuan, which is a significant amount compared to previous years[128]. - The company’s cash dividend policy aligns with its articles of association and dividend management practices[125]. - The company plans to distribute cash dividends amounting to no less than 10% of the distributable profits achieved in each of the next three years following its listing[141]. - Cumulatively, the cash dividends distributed over the three years should not be less than 30% of the average annual distributable profits during that period[141]. - The company emphasizes a stable profit distribution mechanism, prioritizing cash dividends as the main form of profit distribution[142]. - The company will ensure that cash dividends are only distributed when it has positive cumulative undistributed profits and sufficient cash flow[142]. Compliance and Governance - The company has committed to not engaging in any business activities that may directly or indirectly compete with its subsidiary, 中金辐照, ensuring no new similar business entities will be established or acquired[136]. - The company will ensure compliance with all relevant laws and regulations regarding share reduction[135]. - The company will disclose any failure to fulfill commitments promptly, including the specific reasons and actions taken to protect investor rights[148]. - The company will not engage in any form of financial assistance to related parties that could harm shareholder interests[149]. - The company will ensure that all related transactions are conducted according to legal procedures and disclosed in a timely manner[149]. Environmental and Social Responsibility - The company complies with environmental protection regulations, with its subsidiaries meeting national standards for waste disposal[179]. - The company has not conducted any poverty alleviation work during the reporting period and has no subsequent plans[175].